Allogeneic cell banks: one donor, hundreds of doses

Allogeneic (off-the-shelf) cell therapy replaces the one-batch-per-patient process with a banked product. T cells from a screened healthy donor, or immune cells differentiated from an induced pluripotent stem cell line, are gene-edited to remove the T cell receptor (so they cannot cause graft-versus-host disease) and often CD52 or the HLA class I machinery (so they resist rejection or survive an anti-CD52 lymphodepleting antibody), transduced with the CAR, expanded to many billions of cells in a single run, and cryopreserved as a master and working cell bank from which hundreds of doses are drawn. Manufacturing then looks like a conventional biologic, with a defined batch, full release testing and inventory, and the vein-to-vein wait disappears.

Cellectis pioneered the approach with TALEN editing (UCART19, made at its own plants in Paris and Raleigh, North Carolina), Allogene develops cemacabtagene ansegedleucel and other products under a Cellectis licence, Caribou uses CRISPR hybrid guides, and Fate and Century derive cells from iPSC lines. The open problems are biological rather than industrial: edited donor cells persist for a shorter time than a patient's own cells, so responses have often been briefer, deeper lymphodepletion is needed, and regulators have paused programmes over editing safety (the FDA placed Allogene's trials on clinical hold in 2021 after a chromosomal abnormality was found in one patient's cells, and lifted it in early 2022). If durability is solved, the cost and access case is strong: one manufacturing run could treat as many patients as a year of autologous slots.